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Zinc is an essential trace element, whose importance to the function of the
central nervous system (CNS) is increasingly being appreciated. Alterations in zinc
dyshomeostasis has been suggested as a key factor in the development of several
neuropsychiatric disorders. In the CNS, zinc occurs in two forms: the first being tightly
bound to proteins and, secondly, the free, cytoplasmic, or extracellular form found in
presynaptic vesicles. Under normal conditions, zinc released from the synaptic vesicles
modulates both ionotropic and metabotropic post-synaptic receptors. While under clinical
conditions such as traumatic brain injury, stroke or epilepsy, the excess influx of zinc into
neurons has been found to result in neurotoxicity and damage to postsynaptic neurons.
On the other hand, a growing body of evidence suggests that a deficiency, rather than an
excess, of zinc leads to an increased risk for the development of neurological disorders.
Indeed, zinc deficiency has been shown to affect neurogenesis and increase neuronal
apoptosis, which can lead to learning and memory deficits. Altered zinc homeostasis
is also suggested as a risk factor for depression, Alzheimer’s disease (AD), aging, and
other neurodegenerative disorders. Under normal CNS physiology, homeostatic controls
are put in place to avoid the accumulation of excess zinc or its deficiency. This cellular zinc
homeostasis results from the actions of a coordinated regulation effected by different
proteins involved in the uptake, excretion and intracellular storage/trafficking of zinc.
These proteins include membranous transporters (ZnT and Zip) and metallothioneins
(MT) which control intracellular zinc levels. Interestingly, alterations in ZnT and MT have
been recently reported in both aging and AD. This paper provides an overview of both
clinical and experimental evidence that implicates a dysfunction in zinc homeostasis in the
pathophysiology of depression, AD, and aging.
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INTRODUCTION
Knowledge about zinc has rapidly evolved over the years with
the last two decades having brought, interesting new insights
about the role of zinc in molecular and cellular processes as
well as health and disease. Zinc is one of the most preva-
lent trace elements in the human body. It is a key structural
component of a great number of proteins, and a co-factor
of more than 300 enzymes that regulate a variety of cellu-
lar processes and cellular signaling pathways essential for both
brain and systemic physiology (Takeda, 2000). In the brain,
zinc is also present in its free ionic form (Zn2+) within synap-
tic vesicles, mostly at the glutamatergic terminals (Frederickson
et al., 2000; Paoletti et al., 2009; Sensi et al., 2011). Synaptically
released zinc, during neuronal activity, affects the activity
of N-methyl-D-aspartate (NMDA) and α-amino-3-hydroxyl-
5-methyl-4-isoxazole-propionate (AMPA) glutamate receptors,
GABAA and glycine inotropic receptors (Smart et al., 2004). It
has also been found to activate a specific metabotropic Zn2+-
sensing receptor GPR39 (Besser et al., 2009). In physiological con-
centrations zinc exhibits neuroprotective activity, although high
concentrations of zinc are neurotoxic (Choi et al., 1988; Perry
et al., 1997; Cote et al., 2005; Plum et al., 2010). Therefore, an
imbalance of zinc homeostasis will have complex implications in
a number of brain processes then leading to the onset of chronic
pathologies such as depression, schizophrenia, Alzheimer’s dis-
ease (AD), Parkinson’s disease, aging, or amyotrophic lateral
sclerosis (ALS). Given the complex nature of zinc homeostasis
in the brain, it is not surprising that several different groups of
proteins are involved in managing its cellular levels. The first
group consists of are membranous transporters (ZnTs) mediat-
ing the zinc efflux from cells or influx into cellular compartments
or organelles (Huang and Tepaamorndech, 2013). The second
group is members of the Zip family (zinc-regulated and iron-
regulated transporter proteins) that promote zinc transport from
the extracellular space or from intracellular vesicles to the cyto-
plasm (Cousins et al., 2006). So far, 10 members of the ZnT
and 14 members of the ZIP protein families have been identi-
fied (Lichten and Cousins, 2009). The third group of these zinc
homeostasis-regulating proteins is metallothioneins (MTs)—a
group of low-molecular-weight metal-binding proteins that have
a high affinity for zinc (Krezel et al., 2007). Four MT isoforms
have been described so far; MT-I and MT-II are expressed in
many tissues; MT-IV is exclusively expressed in some stratified
squamous epithelia (Quaife et al., 1994) and MT-III. MT-III is
a brain-specific member of the MTs protein family, found exclu-
sively in neurons, and localized predominantly in neurons that
Frontiers in Aging Neuroscience www.frontiersin.org July 2013 | Volume 5 | Article 33 | 1
AGING NEUROSCIENCE
Szewczyk Zinc in neurodegenerative disorders
sequester zinc in synaptic vesicles (Masters et al., 1994). MT-III
mRNA has been found in the cortex, hippocampus, amygdala,
and cerebellum (Masters et al., 1994). The role of MTs is to buffer
cytoplasmic zinc following its influx into the cytoplasm, and so
far it seems that temporary cellular zinc storage is the exclusive
function ofMTs (Krezel et al., 2007). MTs play a crucial protective
role (due to their redox properties) in the presence of radiations,
heavy toxic metals, lipid peroxidation, or reactive oxygen species
(ROS) (Sato and Kondoh, 2002).
The understanding of the physiological functions of zinc trans-
porters and MTs has grown dramatically during recent decade
and their involvement in the pathogenesis of neurodegenerative
diseases more apparent than previously. This review focuses on
depression, AD, and age related pathologies, in which a specific
role for zinc dyshomeostasis has been reported. Also, disease asso-
ciated alterations in proteins responsible for zinc transport and
zinc storage will be discussed.
THE ROLE OF ZINC IN MODULATING SYNAPTIC FUNCTION
There are several important aspects associated with zinc deple-
tion; supplementation and delivery of zinc to the brain.
Experimentally, zinc deficiency is reached by partaking in a diet
that contains 0.5mgZn/kg–6 mgZn/kg for at least 2–4 weeks
(Tamano et al., 2009; Mlyniec et al., 2012). Zinc overdoses can
be obtained at 100mgZn/kg–180 mgZn/kg (Yang et al., 2013).
The most common way for assessing the zinc level is by measur-
ing the serum or plasma zinc. Unfortunately, elevated or lowered
serum zinc does not correspond with the elevated or lowered
brain zinc total. This suggests that the brain zinc total is strictly
controlled and may not be easily influenced by peripheral zinc
level. The other problem is the lack of sensitive methods to mea-
sure alterations in the extra or intracellular zinc levels. Available
data indicates that the hippocampus seems to be the most respon-
sive both to the deficiency as well as an overdose of zinc (Takeda
et al., 2005; Suh et al., 2009; Yang et al., 2013). Because the hip-
pocampus is the region of the brain which plays a critical role
in memory, learning and neurogenesis, the impact of zinc defi-
ciency or zinc supplementation on these processes will be critical.
Indeed, it was found that a zinc deficient diet, decreases the num-
ber of progenitor cells and immature neurons in the dentate gyrus
(DG) in rodents and that reversal to a normal diet containing
zinc restored a number of these cells (Gao et al., 2009; Suh et al.,
2009). Reduced progenitor cells were also found after zinc chela-
tor treatment and in ZnT3 KOmice (a lack of zinc in the synaptic
vesicles) (Suh et al., 2009). A growing body of evidence indi-
cates that dietary zinc deficiency influences hippocampal learning
and memory in an age-dependent manner. It was found that
a decrease in dietary zinc during early development produces
an irreversible deficit of learning and memory, while zinc defi-
cient induced impairments in young adult rats can be reversed
by feeding them with an adequate diet (Takeda, 2000; Keller
et al., 2001). Recent data published by Gao et al. (2009, 2011)
showed that the zinc-deficiency induced hippocampal learning
and memory impairments is in part due to the disruption of the
calmodulin (CaM), CaM-dependent protein kinase II (CaMKII),
and cAMP-responsive element binding protein (CREB) signaling
pathway. As was mentioned above zinc was found to modulate
neural transmission through the GPR39 Zn2+-sensing receptor.
Recent studies showed a significant reduction in the GPR39 pro-
tein level in the frontal cortex in mice receiving the zinc deficient
diet (Mlyniec et al., 2013). This study provides evidence that the
GPR39 Zn2+-sensing receptor may be involved in the pathome-
chanism of depression. This hypothesis was further supported
by data indicating the up-regulation of the GPR39 receptor after
chronic antidepressant treatment (Mlyniec and Nowak, 2013).
The other mechanism by which zinc can modulate synap-
tic functions is the transactivation of the tropomyosin-related
kinase B (TrkB) receptor and activation of brain-derived neu-
rotrophic factor BDNF signaling in a neurotrophic—independent
manner (Huang et al., 2008). Zinc can affect BDNF signaling also
by promoting the maturation of pro-BDNF to BDNF through-
out the activation of metalloproteinases (MMPs) (Hwang et al.,
2005).
Zinc also appears to have an effect of oxidative stress. It
was found that both high and extremely low concentrations of
zinc are associated with increased oxidative and nitrosative stress
[by increasing the expression of neuronal nitric oxide synthase
(nNOS) and NADPH oxidase] (Noh and Koh, 2000; Aimo et al.,
2010), however, intermediate concentrations was found to be
neuroprotective (Aimo et al., 2010). This demonstrates once again
the importance of zinc homeostasis in normal brain function.
Although, the effect of zinc deficiency on the brain zinc home-
ostasis and learning and memory has been well studied, the effect
of a zinc overdose on these processes is poorly described and the
data are rather conflicting. First, the effect of zinc supplementa-
tion on learning and memory impairments is dose dependent.
Generally, zinc supplementation in a low dosage seems to improve
the performance of animals in spatial memory tasks (Piechal
et al., 2012) or the contextual discrimination task (Yang et al.,
2013). However, memory deficits in rats after low dose of zinc
supplementation were also observed (Flinn et al., 2005; Railey
et al., 2010). Interestingly Yang et al. (2013) reported that zinc
supplementation in high doses induce a dramatic decrease in hip-
pocampal zinc levels, especially in the CA3 and DG, and impaired
learning and memory due to a decreased availability of synaptic
zinc and BDNF deficits.
ZINC AND DEPRESSION
Depression is a common mental disorder associated with func-
tional impairment, significant disability, morbidity andmortality.
Despite the extensive research that has so far been carried out
on depression, its pathophysiology is still poorly understood.
One of the many hypotheses proposed for depressive disorder
indicates that depression is characterized by an enhanced neu-
rodegeneration and decreased neurogenesis (Maes et al., 2009).
On the other hand, there is increasing evidence linking depres-
sion or depression-related changes in brain function or cognitive
performance to zinc ion availability.
ZINC LEVELS IN DEPRESSION (TABLE 1)
Clinical studies demonstrate significantly lower serum zinc lev-
els in patients suffering from major depression or unipolar
depression than that in non-depressed patients (McLoughlin and
Hodge, 1990; Maes et al., 1994, 1997; Nowak et al., 1999). In some
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patients, a negative correlation between the serum zinc level and
severity of depression was found (Maes et al., 1994; Nowak et al.,
1999). A lower serum zinc level was also found to accompany
antepartum and postpartum depression. In this study the level
of zinc was also negatively correlated with the severity of depres-
sive symptoms (Wojcik et al., 2006). Low serum zinc levels have
also been noted in depressed patients with end-stage renal dis-
ease undergoing hemodialysis (Roozbeh et al., 2011). Moreover,
treatment-resistant depressed patients have been shown to exhibit
much lower serum zinc concentrations than their non-treatment
resistant depressed counterparts (Siwek et al., 2010). Thus far,
only two studies have reported no differences in the zinc level
between depressed and non-depressed patients (Narang et al.,
1991; Irmisch et al., 2010). The paper published by Irmisch et al.
(2010), however indicated that zinc concentrations might dif-
fer dependent on comorbid disorders and severity of depression.
Similarly, Narang et al. (1991) reported no significant difference
between control and depressed patients, however, they found that
the values were significantly higher in recovered patients com-
pared to patients with depression. Although these results do not
confirm the general hypothesis of a lack of zinc in depressive
disorders, however favor the existence of correlation between
severity of depression or status of patients and zinc concentration.
ZINC DEFICIENCY AND DEPRESSION
There is a paucity of clinical studies that have examined the
relationship between dietary zinc intake and depressive symp-
toms (Table 1). One study, carried out by Amani et al. (2010)
showed that both daily zinc intake and the serum zinc levels in
young depressed women were about two thirds of that observed
in healthy volunteers. Moreover, an inverse correlation was found
between serum zinc concentrations and depression scale scores.
In another study, conducted among a group of pregnant women,
the relationship between dietary zinc intake, psychosocial stress
and sociodemographic factors and depression was examined.
Analysis of the results showed that lower zinc intake, higher stress
and social disadvantage were associated with the occurrence of
depressive symptoms, which were in turn attenuated by higher
zinc intake (Roy et al., 2010). Data coming from animal studies
further support the hypothesis that a deficiency in zinc can lead
to the induction of depressive behavioral symptoms (Table 1).
Studies have shown that zinc-deficient mice exhibit an increased
immobility time in the forced swim test (FST) and tail suspen-
sion test (TST) (Whittle et al., 2009; Mlyniec and Nowak, 2012;
Mlyniec et al., 2012). Pro-depressive-like behavior (increased
immobility in the FST or anhedonia) was also found in rats sub-
jected to zinc-deprivation (Tassabehji et al., 2008; Tamano et al.,
2009; Watanabe et al., 2010)
ZINC TREATMENT/SUPPLEMENTATION IN DEPRESSION
Some clinical studies have shown the beneficial effect of zinc
supplementation in the treatment of depression (Table 1). One
such study by Nowak et al. (2003a), was conducted in depressed
patients, treated with tricyclic antidepressants and selective sero-
tonin reuptake inhibitors supplemented with zinc or a placebo.
Analysis of the Hamilton Depression Rating Scale (HDRS) and
Beck Depression Inventory (BDI) scores revealed that patients
who received the zinc supplementation of antidepressant treat-
ment displayed much lower scores than patients treated with
placebos and antidepressants. A beneficial effect of zinc as an
adjunct agent was also found in treatment-resistant patients
(Siwek et al., 2009). In this placebo-controlled, double blind
study patients were randomized into two groups: the first were
treated with imipramine and received one daily placebo and the
second were treated with imipramine supplemented with zinc.
It was found that zinc supplementation significantly reduced
the depression scores [measured by Clinical Global Impression
(CGI); Montgomery-Asberg Depression Rating Scale (MADRS);
BDI and HDRS] and facilitated the effect of the treatment in
antidepressant treatment resistant patients. No significant differ-
ences in the CGI, MADRS, BDI, and HDRS scores were demon-
strated between zinc and placebo- supplemented antidepressant
treatment non-resistant patients. The benefit of zinc supple-
mentation in patients with major depression has been recently
reported by Ranjbar et al. (2013). This randomized, double-blind,
placebo-controlled trial is the next clinical study indicated that
zinc supplementation in conjunction with antidepressants might
be beneficial for reducing depressive symptoms.
The other study published by Sawada and Yokoi (2010) showed
that young women taking multivitamins and zinc supplements
exhibited a significant reduction in depression and anxiety symp-
toms than women taking only multivitamins. In 2012, Sandstead
published the results from six randomized controlled compar-
ative treatment experiments in Chinese and Mexican-American
low-income children, aged 6–9 years; middle-income US pre-
menopausal women; middle income US adolescents and middle-
income US men, illustrating that subclinical zinc deficiency
changes the brain function and that zinc and micronutrient treat-
ment improves altered brain functions (Sandstead, 2012). Two
studies have so far shown no effect of zinc supplementation on
the improvement of depressive symptoms (Nguyen et al., 2009;
DiGirolamo et al., 2010). However, these studies differ signifi-
cantly from that previously described with respect to both the
patients and the length and quality of applications. The first study
by DiGirolamo et al. (2010) examined the effect of six months
of zinc supplementation on the mental health of school-age chil-
dren. The second study, investigated the impact of combinations
of micronutrient supplements on symptoms of depression rather
than effect of zinc supplementation as a stand-alone. Because
of these methodological limitations in existing studies, further
well-designed, adequately powered research is required.
The beneficial effects of zinc treatment have been also reported
in preclinical studies (Table 1). Zinc administration induced an
antidepressant-like effect (reduction in immobility time) in both
the FST and TST (Kroczka et al., 2000, 2001; Nowak et al., 2003b;
Rosa et al., 2003; Cunha et al., 2008; Franco et al., 2008). Zinc
was also active in different models of depression. In the olfac-
tory bulbectomy (OB) a reduction in the number of trials in the
passive-avoidance test and a decreased OB-induced hyperactivity
in rats after zinc treatment was observed (Nowak et al., 2003b).
While in the chronic mild stress (CMS) model of depression;
zinc reversed the CMS-induced reduction in the consumption
of sucrose in rats (Sowa-Kucma et al., 2008). In chronic unpre-
dictable stress (CUS) in turn, zinc treatment prevented deficits
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Table 1 | Summary of the main clinical and preclinical findings supporting the involvement of zinc in depression.
Serum/plasma zinc status—human data References
↓ Major depressed patients; negative correlation between the serum zinc and severity of depression Maes et al., 1994; Nowak et al., 1999
↓ Depressed patients vs. control Siwek et al., 2010
↓ Patients with affective disorders McLoughlin and Hodge, 1990
↓ Women with antepartum and postpartum depressive symptoms Wojcik et al., 2006
↓ Depressed patients with end-stage renal disease undergoing hemodialysis Roozbeh et al., 2011
↔ Depressed patients; zinc concentrations differ dependent on comorbid disorders and severity of
depression
Irmisch et al., 2010
↔ Depressed patients; significantly higher zinc level in recovered patients compared to patients with
depression
Narang et al., 1991
Effect of zinc deficiency—human study
Correlation between dietary zinc intake and the serum zinc concentrations; the inverse correlation
between serum zinc levels and depression scales
Amani et al., 2010
Zinc intake moderates the association between stress and depressive symptoms Roy et al., 2010
Effect of zinc deficiency—animal study
↑ Immobility time in FST in rats Tassabehji et al., 2008; Tamano et al., 2009;
Watanabe et al., 2010
↑ Immobility time in FST in mice Whittle et al., 2009; Mlyniec et al., 2012
↑ Immobility time in TST in mice Whittle et al., 2009; Mlyniec and Nowak, 2012
↓ Saccharin preference in rat Tassabehji et al., 2008
Effect of zinc treatment/supplementation in depression—clinical trials
Zinc supplementation (25mg/12 weeks) significantly reduced scores in HDRS and BDI when
compared with placebo treatment
Nowak et al., 2003a
Zinc supplementation (25mg/12 weeks) augments the efficacy and speed of onset of therapeutic
response to imipramine treatment, particularly in patients previously non-responsive to
antidepressant pharmacotherapies
Siwek et al., 2009
Zinc supplementation (25mg/12 weeks) significantly reduced HDRS compared to placebo Ranjbar et al., 2013
Women who took multivitamins and zinc (7mg/10 weeks) showed a significant reduction in
anger-hostility score and depression-dejection score in the Profile of Moods State (POMS)
Sawada and Yokoi, 2010
Zinc deficiency changes the brain function but zinc and macronutrient treatment improves altered
brain functions
Sandstead, 2012
Zinc supplementation (10mg/6 months) did not induce differences in mental health outcomes
between zinc and placebo groups, however, increases in serum zinc concentrations were associated
with decreases in internalizing symptoms (depression and anxiety)
DiGirolamo et al., 2010
No effect of zinc supplementation on the improvement of depressive symptoms Nguyen et al., 2009
Effect of zinc treatment—animal study
↓ In immobility time in both FST and TST Kroczka et al., 2000, 2001; Nowak et al., 2003b;
Rosa et al., 2003; Cunha et al., 2008; Franco
et al., 2008
↓ Reduction in the number of trials in the passive-avoidance test in OB model;
↓ OB- induced hyperactivity in open field test in OB model
Zinc reversed the CMS-induced reduction in the consumption of sucrose
Nowak et al., 2003b
Sowa-Kucma et al., 2008
Zinc prevented deficits in the fighting behavior in CUS model Cieslik et al., 2007
Zinc intensifies the effects of standard antidepressants in FST, TST, and CUS Szewczyk et al., 2002, 2009; Rosa et al., 2003;
Cieslik et al., 2007; Cunha et al., 2008
in the fighting behavior of chronically stressed rats (Cieslik et al.,
2007). Moreover, zinc has been found to intensify the effects of
standard antidepressants (IMI, fluoxetine, paroxetine, bupropion,
or citalopram) in the FST, the TST, and CUS (Szewczyk et al.,
2002, 2009; Rosa et al., 2003; Cieslik et al., 2007; Cunha et al.,
2008).
Presented above data strongly indicated the importance of
zinc deficiency in human depression and indicated the benefit
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of zinc supplementation in both the efficacy and the speed
of the therapeutic response to antidepressants treatment. Thus,
the understanding of the mechanisms involved in the antide-
pressant activity of zinc might contribute to the development
of a new therapeutic strategy for the treatment of depression
or depression-related diseases. Published so far data points out
that the modulation of glutamatergic neurotransmission (via the
NMDA or AMPA glutamate receptors), serotonergic transmis-
sion (especially via the 5-HT1A receptor) and regulation of BDNF
level seems to be the most important interactions involved in the
antidepressant-like activity of zinc (Nowak et al., 2004; Sowa-
Kucma et al., 2008; Cichy et al., 2009; Szewczyk et al., 2009,
2010).
ZINC AND ALZHEIMER’S DISEASE
AD is a chronic neurodegenerative disorder and the most com-
mon cause of dementia. It is estimated that AD represents 60–
80% of all dementia cases (Daviglus et al., 2010). The clinical
features of AD vary from stable performance and cognitive health
with only a gradual decline in the short-termmemory to a serious
state of cognitive impairment and into different forms of demen-
tia (deterioration of memory, learning, orientation) (Daviglus
et al., 2010). On the other hand the pathological features of AD
is the accumulation of β-amyloid (Aβ) and the aggregation of Aβ
is suggested as the cause of neurodegeneration observed in AD
(Small and Cappai, 2006).
Although the key role of Aβ in the pathogenesis of AD is
strongly established now, the mechanism by which Aβ induces
toxicity or the causes and factors associated with the risk or pro-
gression of AD is still poorly understood. One of the several
hypotheses proposed for the pathophysiology of AD is the trace
elements hypothesis, with zinc taking the center stage. Zinc was
first described as a possible factor leading to dementia by Burnet
(1981) and, since then, the knowledge base regarding the role of
zinc in the pathogenesis and therapy of AD has evolved rapidly.
ZINC LEVELS IN AD
Serum, cerebrospinal fluid (CSF) and brain zinc levels have been
investigated in patients diagnosed with AD (Table 2). Several of
these studies investigating serum zinc levels have shown either
divergent data with no differences (Shore et al., 1984; Haines
et al., 1991), a significant decrease (Jeandel et al., 1989; Baum
et al., 2010; Brewer et al., 2010; Vural et al., 2010) or a significant
increase (Gonzalez et al., 1999; Rulon et al., 2000) when com-
pared to matched controls. The main problem associated with
these clinical studies is that different methodologies and different
selections of patients were used meaning that the end result could
account for the various divergent data obtained in the studies.
Studies looking at CSF zinc levels also showed some discrepancies.
For instance, Hershey et al. (1983) and Sahu et al. (1988) found no
differences in CSF levels of zinc in patients with dementia of the
Alzheimer type relative to a matched group of healthy controls. In
contrast, Molina et al. (1998) found a significant decrease in CSF
zinc levels in AD patients than the control subjects.
Studies investigating zinc content in brain tissue suggests that
an alteration in the zinc level seems to be fraction/region spe-
cific. Studies involving whole tissue samples have shown no
differences in brain zinc levels between AD and the control sub-
jects. Although, some alterations in the brain zinc levels were
found when tissue was sub-fractionated (a decrease in nuclear but
not in mitochondrial or microsomal fractions) or when different
brain regions were analyzed separately (Wenstrup et al., 1990).
Indeed, decreased zinc levels have been found in the neocortex,
medial temporal gyrus, thalamus, and hippocampus (Corrigan
et al., 1993; Panayi et al., 2002), whilst increased levels were found
in the amygdala, hippocampus, cerebellum, olfactory areas and
superior temporal gyrus (Thompson et al., 1988; Samudralwar
et al., 1995; Danscher et al., 1997; Religa et al., 2006). The above
mentioned data, even though inconsistent, strongly support the
hypothesis that a deregulated zinc homeostasis is involved in the
pathophysiology of AD.
ROLE OF ZINC IN AD—POSSIBLE MOLECULAR MECHANISMS
Amongst all the multiple roles of zinc in the pathogenesis of
AD, the most widely studied is the involvement of zinc in the
accumulation of Aβ. Post-mortem studies using different imag-
ing techniques for zinc analysis have demonstrated significant
increases in zinc levels in neuropil and plaques present in the
brain of AD patients when compared to normal age-matched
controls (Lovell et al., 1998; Suh et al., 2000; Dong et al., 2003;
Miller et al., 2006). On the other hand, lack of synaptic zinc
prevents Aβ deposition (Lee et al., 2002).
Aβ is the product of proteolytic cleavage from the amyloid
precursor protein (APP) by the enzyme known as β-secretase or
β-site APP cleaving enzyme-1 (BACE-1) (Masters et al., 1985).
Several pathways for the involvement of zinc in APP processing
or Aβ aggregation has been suggested. It was found that APP syn-
thesis is regulated by zinc-containing transcription factors NF-κB
and sp1 (Grilli et al., 1996). Zinc is also involved in processing
of APP protein (Lee et al., 2009). The processing of APP relies
on a number of activities by enzymes secretases (α-,β-, and γ-).
The predominant route by which APP is processed in the brain
is cleavage by the α-secretase, within the Aβ region, producing
sAPP (soluble amyloid precursor peptide) (Ling et al., 2003).
Further processing by the β-secretase and γ-secretase leads to
the formation of Aβ peptide (Wilquet and De, 2004). It was
found that APP contains a specific zinc binding site localized in
the cysteine-rich region of the APP ectodomain (spanning the
α-secretase position) (Bush et al., 1994b) and it is suggested that
changes in the intracellular concentration of zinc may influence
the relative activities of APP secretases (Bush et al., 1994a,b).
However, is worth mentioning that zinc is clearly not the only
factor influencing APP processing and its role has not been fully
determined.
Recent evidence suggests that oxidative stress is an additional
factor contributing to the progression of AD (Butterfield et al.,
2001; Jomova et al., 2010) and that ROS or exogenous oxidants
are able to promote a harmful zinc release from MTs (Aizenman
et al., 2000; Bossy-Wetzel et al., 2004). Zinc accumulation can in
turn, induce mitochondrial dysfunction and further ROS gen-
eration (Sensi et al., 2003). Results presented by Sensi et al.
(2008) indicate that such ROS-dependent intraneuronal zinc rises
are particularly high in AD neurons expressing mutant APP,
presenilin-1 (PS-1) and tau (Sensi et al., 2008).
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Table 2 | Summary of the main clinical and preclinical findings supporting the involvement of zinc in AD.
Serum/CSF/brain zinc status—human data References
↔ Serum zinc level in patients with and without cognitive impairment in the community
↔ Serum and hair zinc concentration in patients with AD
Haines et al., 1991
Shore et al., 1984
↑ Serum zinc level in AD epsilon 4 apoE allele carriers
↑ Zinc serum in AD subjects compared with age-matched control subjects-postmortem study
Gonzalez et al., 1999
Rulon et al., 2000
↓ Serum zinc level in AD patients
↓ Blood zinc in patients with AD than in controls
↓ Serum zinc level in patients with senile dementia of the Alzheimer type (SDAT) when compared to
control subjects
↓ Plasma zinc level in patients with AD compared with controls
Baum et al., 2010
Brewer et al., 2010
Jeandel et al., 1989
Vural et al., 2010
↔ In CSF zinc level in patients with dementia of the Alzheimer type
↓ CSF zinc levels in AD patients as compared with controls
Hershey et al., 1983; Sahu et al.,
1988
Molina et al., 1998
↓ Hippocampal zinc concentration in patients with AD—postmortem study
↓ Zinc level in both hemispheres of the superior frontal gyrus, the superior parietal gyrus, the medial
temporal gyrus, the hippocampus and the thalamus in the AD patients—postmortem study
↑ Zinc level in hippocampus and amygdala in AD patients—postmortem study
↑ Tissue zinc in the AD-affected cortex compared with the control group
↑ Zinc in olfactory regions of AD patients as compared to control subjects
↑ Zinc in amygdala and hippocampus in AD patients as compared to controls
Corrigan et al., 1993
Panayi et al., 2002
Danscher et al., 1997
Religa et al., 2006
Samudralwar et al., 1995
Thompson et al., 1988
Zinc dyshomeostasis as a new therapeutic target in AD—animal study
Administration of DP-109 (the lipophilic metal chelator) reduced the aggregation of Aβ protein and
deposition of amyloid plaques in aged female hAbetaPP-transgenic Tg2576 mice, compared to animals
receiving vehicle treatment
Lee et al., 2004
Clioqunol (metal chelator) reduced zinc accumulation in the neuritic plaques and inhibit amyloidogenic
AβPP processing in the AβPP/PS1 mouse brain
Wang et al., 2012
Carnosine supplementation in 3 × Tg-AD mice promotes a strong reduction in the hippocampal
intraneuronal accumulation of Aβ and completely rescues AD and aging-related mitochondrial
dysfunctions
Corona et al., 2011
Selective intracellular release of zinc ions from bis(thiosemicarbazonato) complexes reduces levels of
Alzheimer disease amyloid-beta peptide
Donnelly et al., 2008
Presenilins are important for cellular zinc turnover and has the potential to indirectly impact β-amyloid
aggregation through metal ion clearance
Greenough et al., 2011
Zinc supplementation delays hippocampal-dependent memory deficits and reduces both Aβ and tau
pathology in the hippocampus
Corona et al., 2010
Zinc dyshomeostasis as a new therapeutic target in AD—human study
PBT2 (copper/zinc ionophore) lowered CSF levels of Aβ and significantly improved cognition in AD
patients
Lannfelt et al., 2008; Faux et al., 2010
ZINC DYSHOMEOSTASIS AS A NEW THERAPEUTIC TARGET IN AD
Considering the fact that zinc contributes to the aggregation of
the Aβ protein and deposition of amyloid plaques in AD, research
has been focused on the use of metal complexation ability as
therapeutic agents in AD (Table 2). Indeed, the metal chela-
tor, clioquinol (CQ) and zinc modulator—DP-109 were found
to significantly decrease the formation of amyloid plaques in
the brains of APP/PS1 double transgenic mice and aged female
hAbetaPP-transgenic Tg2576 mice, respectively (Lee et al., 2004;
Wang et al., 2012). Faux et al. (2010) describes a successful
phase 2 clinical trial of the quinoline derivative, PBT2 in AD
(Faux et al., 2010). This randomized, placebo controlled trial
found that this metal-protein attenuating compound (MPAC)
that affects the Cu2(+)-mediated and Zn2(+)-mediated toxic
oligomerization of Abeta seen in AD significantly lowered the CSF
levels of Aβ and significantly improved cognition in AD patients
(Lannfelt et al., 2008; Faux et al., 2010). The other possible ther-
apeutic compound for AD, suggested recently is carnosine—a
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peptide with cooper/zinc chelating properties (Trombley et al.,
1998). Corona et al. (2011) found that dietary supplementation
of carnosine reduces hippocampal intraneuronal accumulation of
Aβ and rescues mitochondrial dysfunctions in triple-transgenic
AD mice (3 × Tg-AD) but does not affect the development of the
tau pathology and only slightly reduces cognitive deficits (Corona
et al., 2011). Furthermore, the paper of Donnelly et al. (2008)
demonstrated the beneficial effect of the selective intracellular
delivery of zinc using bis(thiosemicarbazonato) complexes in the
reduction of the extracellular levels of Aβ and suggested the role
of these metal-loaded compounds as potential therapeutic agents
for AD (Donnelly et al., 2008). In turn Greenough et al. (2011)
reported that presenilin, which mediates the proteolytic cleav-
age of the β-amyloid precursor protein to release β-amyloid, is
important for cellular cooper/zinc turnover and has the poten-
tial to indirectly impact on amyloid aggregation through zinc ion
clearance (Greenough et al., 2011).
Interestingly, a delay in hippocampal-dependent memory
deficits and reduction of both the Aβ and tau pathology in the
hippocampus in 3 × Tg-AD mice was also observed after zinc
supplementation (Corona et al., 2010). This study also indi-
cated the involvement of the BDNF-tyrosine kinase type B (TrkB)
receptor pathway in the mechanism of the beneficial effect of zinc
supplementation in this AD model (Corona et al., 2010).
All of these data further emphasizes the integral role of zinc in
the mechanism of AD and support the hypothesis that restoring
zinc homeostasis might be beneficial in the treatment of AD,
although it also indicated the complex interactions between AD
and zinc.
ROLE OF METALLOTHIONEINS AND ZINC TRANSPORTERS IN AD
There are several proteins/pathways that interact with zinc and
that are also relevant to AD (Figure 1). One of these is MT. As
noted earlier, MTs are zinc- binding proteins involved in the reg-
ulation of the transport, storage and transfer of zinc to various
enzymes and transcription factors (Liuzzi and Cousins, 2004;
DiGirolamo et al., 2010). The involvement of MTs in the reg-
ulation of zinc homeostasis makes it important in the context
of the Zinc hypothesis of AD. Indeed, there are a number of
studies that have reported increases, decreases and no change
in MT isoforms in the brain. The study published by Adlard
et al. (1998) showed a significant increase in MT I/II in the
gray matter of preclinical AD cases when compared to non-
AD cases. The authors suggested that the increase in MT I/II
might be associated with the initial stages of AD processes due
to the oxidative stress or alterations in the metabolism of heavy
metals (Adlard et al., 1998). MT-III, also known as the growth
inhibitory factor (GIF) was found to be down-regulated in the
AD cortex (Uchida et al., 1991; Tsuji et al., 1992; Cuajungco
and Lees, 1997; Yu et al., 2001), although no changes in the
MT-III level in AD was also observed (Erickson et al., 1994;
Amoureux et al., 1997). These discrepancies across different stud-
ies may result from the stage of the disease or cellular zinc status.
Another important group of proteins involved in the homeostasis
FIGURE 1 | Cellular localization of zinc transporters and metallothioneins and summary of the main clinical and preclinical findings supporting the
involvement of these proteins in AD.
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of zinc and the pathogenesis of AD are zinc transporter (ZnTs)
proteins. Zhang et al. (2008) showed that six ZnTs such as:
1–7 are extensively present in the Aβ, being therefore positive
plaques in the cortex of human AD brains. Recent studies showed
alterations in levels of ZnTs proteins in the brain of subjects diag-
nosed with the preclinical stage of AD (PCAD), mild cognitive
impairment (MCI), early (EAD), and the late (LAD) stage of
AD when compared to the control subjects (Lovell et al., 2005,
2006; Smith et al., 2006; Lovell, 2009; Lyubartseva et al., 2010;
Lyubartseva and Lovell, 2012). Human postmortem brain tis-
sue from Braak-staged individuals with AD displayed a reduced
expression of ZnT-3 mRNA (Beyer et al., 2009) and increased
mRNA levels of the other more established zinc transporters,
such as LIV1, ZIP1, ZnT1, ZnT6 in the AD cortex (Beyer et al.,
2012). Also animal studies have linked dyshomeostasis in the
brain zinc level to the pathogenesis and progression of AD. Lee
et al. (2002) using a ZnT-3 null mice crossed with mice express-
ing mutant APP showed that the absence of synaptic zinc reduces
the plaque load and increases the ratio of soluble/insoluble Aβ
species. As such, this data suggested that synaptic zinc plays a key
role in Aβ aggregation and plaque accumulation. Other studies
also reported that with aging, female mice exhibit higher lev-
els of synaptic, insoluble Aβ and plaques than males and that
these sex differences disappeared in ZnT-3 knockout mice, cor-
relating with the well described age-adjusted increase incidence
for AD in females rather than males (Katzman et al., 1989).
Recent studies published by Zhang et al. (2010) showed sig-
nificant increases of ZnT-1, ZnT-3, ZnT-4, ZnT-6, and ZnT-7
in the hippocampus and neocortex of APPswe/PS1dE9 trans-
genic mice which corresponding to a form of early onset AD.
Lang et al. (2012) in turn demonstrated that over-expression of
Drosophila homolog of human Zip1 results in zinc accumulation
in Aβ42–expressing fly brains and that inhibition of Zip1 expres-
sion induces a reduction of Aβ42 fibril deposits and improves
cognition (Lang et al., 2012).
ZINC IN BRAIN AGING
Aging is an inevitable process associated with progressive patho-
logical features such as: oxidative stress, altered cell metabolism,
damaged of nucleic acid, or deposition of abnormal forms of
proteins. In the brain aging is characterized by neuronal loss, cog-
nitive impairment, and susceptibility to neurological disorders
(Mocchegiani et al., 2005).
Recent progress in studies involving age related processes pro-
vide evidence that changes occurring in the brain during aging are
related to zinc homeostasis and that zinc deficiency is a common
cause of morbidity among the elderly (Mocchegiani et al., 2005).
In aging, zinc deficiency is usually the result of an inadequate zinc
dietary intake. It has been reported that only 40% of elderly peo-
ple have a sufficient intake of zinc (Andriollo-Sanchez et al., 2005;
Mocchegiani et al., 2008). Studies comparing old and young mice
fed with low dietary zinc indicated that zinc is an important nutri-
tional factor for a proper inflammatory/immune response (Kelly
et al., 1996). Accordingly, zinc has anti-inflammatory properties
and a low zinc status is associated with increased susceptibility to
infection plus intracellular zinc has been found to play a key role
in signaling in immune cells (Haase and Rink, 2009; Hasan et al.,
2012). On the other hand aging is characterized by the progressive
dysregulation of immune responses. Therefore, zinc has been sug-
gested as a good factor in providing the remodeling of some age-
associated changes and also as leading to healthy ageing through
the reduction of inflammation (Kahmann et al., 2008). The study
by Wong et al. (2013) suggests that age-related epigenetic dys-
regulation in ZnT expression may change cellular zinc levels
and increase inflammation with age. They found that reduced
Zip6 expression enhanced proinflammatory responses and that
this age-induced Zip6 dysregulation correlated with an increased
Zip6 promoter methylation. Interestingly, dietary supplementa-
tion reduced aged-associated inflammation (Wong et al., 2013).
The other mechanism linking age, zinc and inflammation is asso-
ciated with MTs. It was found that ageing is associated with a
higher MT expression and consequently, low availability of intra-
cellular zinc for normal immune responses. On the other hand,
the supplementation of zinc in aging improves immune function
and leads to decreased mortality from infections (Mocchegiani
et al., 2010). In another study, Mocchegiani et al. (2011)
showed evidence that zinc deficiency and an altered immune
response is more evident in people with a polymorphism in
IL-6 and metal-response element binding transcription factor-1
(MT1A) and that these individuals will benefit more from zinc
supplementation.
CONCLUSIONS
From the foregoing results, it is obvious that zinc homeostasis
may play a major role in the initiation and propagation of the
pathological features of psychiatric and neurodegenerative dis-
orders. However, more studies are needed to explain the exact
mechanisms linking zinc and processes related to these diseases.
First, since zinc deficiency is prevalent in patients with psy-
chiatric and neurodegenerative disorders, the appropriate pre-
ventive measures should be considered especially in the elderly.
Conversely, even if the beneficial effects of zinc supplementation
were reported either in treatment or in the prevention of depres-
sive or aging symptoms, zinc supplement users should be overly
cautious and avoid overdosing.
Some of the studies presented above suggest that zinc can be
useful not only by itself but in combination with other drugs used
in treatment. Other important aspects in the context of zinc and
treatment of patients aremetal chelating drugs, for which the pos-
itive effect was particularly emphasized in AD. The weakness in
most of these drugs, however, are the side effects caused by the
chelation of other important divalent metal ions in the brain.
Chelation should thus be used only when the brain zinc level is
expected to have neurotoxic effects.
Recently, the zinc-homeostasis regulating proteins such as
transporters and MTs have been gaining more prominence in
related literature indicating they may be very important players in
the pathophysiology of neurodegenerative disorders. Therefore,
more studies are needed to fully understand the influence of
peripheral zinc deficiency or an overdose on these proteins.
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